Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body × Cetuximab × 90 days × Clear all

NCT07252739 2026-03-16

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms